ArticleFrontiers in public health2026
Policy text analysis of China's smart pharmaceutical regulation under a policy tool-policy stage framework.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Smart pharmaceutical regulation has emerged as a key approach to enhancing regulatory capacity and ensuring drug safety in the context of digital government. However, existing studies have largely focused on technological applications or descriptive policy analyses, with limited attention to the structural characteristics and evolution of policy instruments. To address this gap, this study applies a two-dimensional analytical framework that integrates policy instruments and policy development stages to examine China's smart pharmaceutical regulation policies. Drawing on a dataset of 90 policy documents issued between 2007 and 2026, the study employs a content-analysis approach, using the Nodality, Authority, Treasure, and Organization (NATO) framework to classify policy instruments and NVivo software to support systematic coding. The findings showed that nodality-based instruments constitute the largest share of the policy texts, reflecting a strong policy emphasis on data-driven governance, information sharing, and digital regulatory capacities. Treasure-based instruments primarily focus on digital infrastructure and technical-capacity development, while authority-based instruments continue to play an important role alongside emerging digital regulatory tools. Conversely, organization-based instruments receive comparatively less emphasis in the policy text, particularly regarding institutional coordination and stakeholder co-governance. From a temporal perspective, the policy texts reflect a shift from informationization-oriented regulation toward digital integration and, more recently, toward lifecycle-based and intelligence-oriented regulatory arrangements. Nevertheless, structural imbalances in the distribution of policy instruments remain evident within the policy corpus. The findings suggest the importance of strengthening interagency coordination, stakeholder participation, and the integration of technological and institutional governance mechanisms in future policy design. This study contributes to the literature by providing a systematic policy text analysis of smart pharmaceutical regulation and offering insights into the evolving structure of regulatory governance in the digital age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.